Armenia - englanti - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

gedeon richter plc - chlormadinone (chlormadinone acetate), ethinylestradiol - tablets film-coated - 2mg+ 0,03mg

Saudi-Arabia - englanti - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

aja pharmaceutical industries - chlormadinone acetate, ethinylestradiol - film-coated tablet - 2 , 0.03 mg

Filippiinit - englanti - FDA (Food And Drug Administration)

pharmasia-cuvest, incorporated; distributor: pharmasia-cuvest, incorporated - chlormadinone acetate , ethinylestradiol - film-coated tablet - 2mg/ 30mcg

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - ethinylestradiol 2.7mg (15µg/24h elution rate in-vivo);  ; etonogestrel 11.7mg (120µg/24h elution rate in-vivo);   - vaginal ring - 120mcg etonogestrel, 15mcg ethinylestradiol / 24h - active: ethinylestradiol 2.7mg (15µg/24h elution rate in-vivo)   etonogestrel 11.7mg (120µg/24h elution rate in-vivo)   excipient: evatane 1020 vn3 ethylene/vinyl acetate co-polymer evatane 28-25 ethylene/vinyl acetate co-polymer magnesium stearate - contraception.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - desogestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet - excipient ingredients: povidone; titanium dioxide; magnesium stearate; maize starch; hypromellose; polysorbate 80; triacetin; indigo carmine aluminium lake; colloidal anhydrous silica; iron oxide yellow; lactose monohydrate - oral contraception

Australia - englanti - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - nomegestrol acetate, quantity: 2.5 mg; estradiol hemihydrate, quantity: 1.55 mg (equivalent: estradiol, qty 1.5 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; purified talc; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - oral contraception.

Japani - englanti - すりの適正使用協議会 RAD-AR Council, Japan

kyosomirai pharma co., ltd. - chlormadinone acetate - pale yellow tablet, diameter: approx. 7 mm, thickness: approx. 3 mm

Australia - englanti - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - desogestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet - excipient ingredients: magnesium stearate; lactose monohydrate; potato starch - oral contraception.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate - indicated for the treatment of signs of androgenisation in women such as severe acne (involving inflammation or nordularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. jene-35ed will also provide effective oral contraception in this patient group. if the hirsutism has only recently appeared or has lately intensified to a considerable extent, the cause (androgen-producing tumour or an adrenal enzyme defect) must be clarified by differential diagnosis.

Israel - englanti - Ministry of Health

bayer israel ltd - drospirenone; ethinylestradiol as betadex clathrate; levomefolate calcium; levomefolate calcium - film coated tablets - levomefolate calcium 0.451 mg; ethinylestradiol as betadex clathrate 0.02 mg; drospirenone 3 mg; levomefolate calcium 0.451 mg - estradiol, combinations - - oral contraception. - treatment of symptoms of premenstrual dysphoric disorder (pmdd ) in women who choose to use an oral contraceptive as their method of birth control.- treatment of moderate acne vulgaris in women at least 14 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. - in women who choose to use an oral contraceptive as their method of contraception, to raise folate levels for the purpose of reducing the risk of a neural tube defect in a pregnancy conceived while taking the product or shortly after discontinuing the product.